← 홈

CGT

275개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 275개
CGTBiologicstaleQi dengPreclinical

CD7 CART (CD7 CART)

CD7+ Lymphoma; CD7+ Acute Leukemia · CD7+ Lymphoma

#CD7+Lymphoma#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleGracell Biotechnologies (Shangh…Phase 1

CD7 UCAR-T cells (CD7 UCAR-T cells)

T-cell Leukemia; T-cell Lymphoma · T-cell Leukemia

#T-cellLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBambino Gesù Hospital and Resea…Phase 2

CD7-CART01 (CD7-CART01)

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

CD7-specific CAR gene-engineered T cells (CD7-specific CAR gene-engineered T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

CD70 CAR-NK (CD70 CAR-NK)

Relapsed/Refractory T-cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR)

Juvenile Myelomonocytic Leukemia; Recurrent Acute Biphenotypic Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Boren HospitalPhase 1

0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg (CI-135 CAR-T cells, CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg))

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 1

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBaylor College of MedicinePhase 1

CLL-1.CAR T cells (CLL-1.CAR T cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 RECRUITING
CGTBiologicstaleGuangzhou Bio-gene Technology C…Preclinical

CLL1+CD33 CAR-T (CLL1+CD33 CAR-T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CLL1-CD33 cCAR T cells (CLL1-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMEI HENGPhase 1

CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleChi Kong LiPhase 2

CUCART19 (CUCART19)

Lymphoma, Nonhodgkin; Leukemia, Lymphocytic · Lymphoma, Nonhodgkin

#LymphomaNonhodgkin#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleJohn ListerPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleMasonic Cancer Center, Universi…Phase 2

Donor TCR α/β-depleted Graft/ATG (Donor TCR α/β-depleted Graft/ATG)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING

10 / 14 페이지

← 이전다음 →